Screener
Bristol-Myers Squibb BMY Debt-to-equity
Debt-to-equity at other companies
Other financials
Where this comes from
Calculated from Bristol-Myers Squibb’s reported figures.
Based on the most recent quarter.
The source filing: Bristol-Myers Squibb’s 10-Q, filed July 30, 2026. Open the filing →
- Filed
- Jul 30, 2026, 11:10 AM EDT
- Fiscal quarter
- Q2 FY2026
- Calendar quarter
- Q2 2026
- Accession
- 0000014272-26-000020
FAQ
- What is Bristol-Myers Squibb's debt-to-equity?
- Bristol-Myers Squibb (BMY) reported debt-to-equity of 1.9× in Q2 2026.
- How has Bristol-Myers Squibb's debt-to-equity changed year-over-year?
- Bristol-Myers Squibb's debt-to-equity decreased by 31.5% year-over-year, from 2.8× to 1.9×.
- What is the long-term trend for Bristol-Myers Squibb's debt-to-equity?
- Over 5 years (2020 to 2025), Bristol-Myers Squibb's debt-to-equity has grown at a 13.2% compound annual growth rate (CAGR), from 1.4× to 2.6×.
- What does debt-to-equity mean?
- Total debt (including capitalized leases and financing obligations) divided by shareholders' equity at the quarter end. Measures how much the company is financed by debt relative to equity.
Ask your AI about Bristol-Myers Squibb's debt-to-equity.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude